Loading
A phase 2 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Fudan University, not yet recruiting.
SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer is a phase 2, interventional study registered as NCT07837362 by Fudan University, with a registry enrolment figure of 34 participants, started 2026-09-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Shor-course radiotherapy; PD-1/CTLA4 Antibody; Capecitabine; Oxaliplatin. Conditions listed: Early Low Rectal Cancer. Primary outcome: complete response (CR) rate. Sites: China. No results are recorded here; the registry entry is the source.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Capecitabine, Platinum agents, IMRT / IGRT (modern external beam) and the tag colorectal-deep-dive.